Promising application of metformin in Alzheimer's disease

Alzheimer's disease (AD) is one of the most devastating brain disorders. Currently, there are no effective treatments to stop the disease progression and it is becoming a major public health concern. Several risk factors are involved in the progression of AD, modifying neuronal circuits and...

Descripción completa

Detalles Bibliográficos
Autores: Rabiei Poor, Saghar, Ettcheto Arriola, Miren, Cano Fernández, Amanda, Sánchez-López, E. (Elena), Manzine, Patricia, Olloquequi, Jordi, Camins Espuny, Antoni, Javan, Mohammad
Tipo de recurso: artículo
Estado:Versión publicada
Fecha de publicación:2021
País:España
Institución:Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)
Repositorio:Recercat. Dipósit de la Recerca de Catalunya
OAI Identifier:oai:recercat.cat:2445/181358
Acceso en línea:https://hdl.handle.net/2445/181358
Access Level:acceso abierto
Palabra clave:Malaltia d&apos
Alzheimer
Diabetis
Resistència a la insulina
Metformina
Alzheimer&apos
s disease
Diabetes
Insulin resistance
Metformin
id ES_ed68e6206a22ca0e7efdfa80dfd2f4e7
oai_identifier_str oai:recercat.cat:2445/181358
network_acronym_str ES
network_name_str España
repository_id_str
spelling Promising application of metformin in Alzheimer's diseaseRabiei Poor, SagharEttcheto Arriola, MirenCano Fernández, AmandaSánchez-López, E. (Elena)Manzine, PatriciaOlloquequi, JordiCamins Espuny, AntoniJavan, MohammadMalaltia d&aposAlzheimerDiabetisResistència a la insulinaMetforminaAlzheimer&aposs diseaseDiabetesInsulin resistanceMetforminAlzheimer's disease (AD) is one of the most devastating brain disorders. Currently, there are no effective treatments to stop the disease progression and it is becoming a major public health concern. Several risk factors are involved in the progression of AD, modifying neuronal circuits and brain cognition, and eventually leading to neuronal death. Among them, obesity and type 2 diabetes mellitus (T2DM) have attracted increasing attention, since brain insulin resistance can contribute to neurodegeneration. Consequently, AD has been referred to "type 3 diabetes" and antidiabetic medications such as intranasal insulin, glitazones, metformin or liraglutide are being tested as possible alternatives. Metformin, a first line antihyperglycemic medication, is a 5′-adenosine monophosphate (AMP)-activated protein kinase (AMPK) activator hypothesized to act as a geroprotective agent. However, studies on its association with age-related cognitive decline have shown controversial results with positive and negative findings. In spite of this, metformin shows positive benefits such as anti-inflammatory effects, accelerated neurogenesis, strengthened memory, and prolonged life expectancy. Moreover, it has been recently demonstrated that metformin enhances synaptophysin, sirtuin-1, AMPK, and brain-derived neuronal factor (BDNF) immunoreactivity, which are essential markers of plasticity. The present review discusses the numerous studies which have explored (1) the neuropathological hallmarks of AD, (2) association of type 2 diabetes with AD, and (3) the potential therapeutic effects of metformin on AD and preclinical models. Keywords: Alzheimer's disease; diabetes mellitus; metformin; insulin resistance; beta amyloid; tau protein hyperphosphorylation; AMP activated protein kinase (AMPK)MDPI2021202120212021info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionapplication/pdfhttps://hdl.handle.net/2445/181358Articles publicats en revistes (Farmàcia, Tecnologia Farmacèutica i Fisicoquímica)reponame:Recercat. Dipósit de la Recerca de Catalunyainstname:Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)InglésReproducció del document publicat a: https://doi.org/10.3390/ph14090890Pharmaceuticals, 2021, vol. 14, num. 9https://doi.org/10.3390/ph14090890cc-by (c) Rabiei Poor, Saghar et al., 2021https://creativecommons.org/licenses/by/4.0/info:eu-repo/semantics/openAccessoai:recercat.cat:2445/1813582026-05-29T05:05:01Z
dc.title.none.fl_str_mv Promising application of metformin in Alzheimer's disease
title Promising application of metformin in Alzheimer's disease
spellingShingle Promising application of metformin in Alzheimer's disease
Rabiei Poor, Saghar
Malaltia d&apos
Alzheimer
Diabetis
Resistència a la insulina
Metformina
Alzheimer&apos
s disease
Diabetes
Insulin resistance
Metformin
title_short Promising application of metformin in Alzheimer's disease
title_full Promising application of metformin in Alzheimer's disease
title_fullStr Promising application of metformin in Alzheimer's disease
title_full_unstemmed Promising application of metformin in Alzheimer's disease
title_sort Promising application of metformin in Alzheimer's disease
dc.creator.none.fl_str_mv Rabiei Poor, Saghar
Ettcheto Arriola, Miren
Cano Fernández, Amanda
Sánchez-López, E. (Elena)
Manzine, Patricia
Olloquequi, Jordi
Camins Espuny, Antoni
Javan, Mohammad
author Rabiei Poor, Saghar
author_facet Rabiei Poor, Saghar
Ettcheto Arriola, Miren
Cano Fernández, Amanda
Sánchez-López, E. (Elena)
Manzine, Patricia
Olloquequi, Jordi
Camins Espuny, Antoni
Javan, Mohammad
author_role author
author2 Ettcheto Arriola, Miren
Cano Fernández, Amanda
Sánchez-López, E. (Elena)
Manzine, Patricia
Olloquequi, Jordi
Camins Espuny, Antoni
Javan, Mohammad
author2_role author
author
author
author
author
author
author
dc.subject.none.fl_str_mv Malaltia d&apos
Alzheimer
Diabetis
Resistència a la insulina
Metformina
Alzheimer&apos
s disease
Diabetes
Insulin resistance
Metformin
topic Malaltia d&apos
Alzheimer
Diabetis
Resistència a la insulina
Metformina
Alzheimer&apos
s disease
Diabetes
Insulin resistance
Metformin
description Alzheimer's disease (AD) is one of the most devastating brain disorders. Currently, there are no effective treatments to stop the disease progression and it is becoming a major public health concern. Several risk factors are involved in the progression of AD, modifying neuronal circuits and brain cognition, and eventually leading to neuronal death. Among them, obesity and type 2 diabetes mellitus (T2DM) have attracted increasing attention, since brain insulin resistance can contribute to neurodegeneration. Consequently, AD has been referred to "type 3 diabetes" and antidiabetic medications such as intranasal insulin, glitazones, metformin or liraglutide are being tested as possible alternatives. Metformin, a first line antihyperglycemic medication, is a 5′-adenosine monophosphate (AMP)-activated protein kinase (AMPK) activator hypothesized to act as a geroprotective agent. However, studies on its association with age-related cognitive decline have shown controversial results with positive and negative findings. In spite of this, metformin shows positive benefits such as anti-inflammatory effects, accelerated neurogenesis, strengthened memory, and prolonged life expectancy. Moreover, it has been recently demonstrated that metformin enhances synaptophysin, sirtuin-1, AMPK, and brain-derived neuronal factor (BDNF) immunoreactivity, which are essential markers of plasticity. The present review discusses the numerous studies which have explored (1) the neuropathological hallmarks of AD, (2) association of type 2 diabetes with AD, and (3) the potential therapeutic effects of metformin on AD and preclinical models. Keywords: Alzheimer's disease; diabetes mellitus; metformin; insulin resistance; beta amyloid; tau protein hyperphosphorylation; AMP activated protein kinase (AMPK)
publishDate 2021
dc.date.none.fl_str_mv 2021
2021
2021
2021
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv https://hdl.handle.net/2445/181358
url https://hdl.handle.net/2445/181358
dc.language.none.fl_str_mv Inglés
language_invalid_str_mv Inglés
dc.relation.none.fl_str_mv Reproducció del document publicat a: https://doi.org/10.3390/ph14090890
Pharmaceuticals, 2021, vol. 14, num. 9
https://doi.org/10.3390/ph14090890
dc.rights.none.fl_str_mv cc-by (c) Rabiei Poor, Saghar et al., 2021
https://creativecommons.org/licenses/by/4.0/
info:eu-repo/semantics/openAccess
rights_invalid_str_mv cc-by (c) Rabiei Poor, Saghar et al., 2021
https://creativecommons.org/licenses/by/4.0/
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv MDPI
publisher.none.fl_str_mv MDPI
dc.source.none.fl_str_mv Articles publicats en revistes (Farmàcia, Tecnologia Farmacèutica i Fisicoquímica)
reponame:Recercat. Dipósit de la Recerca de Catalunya
instname:Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)
instname_str Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)
reponame_str Recercat. Dipósit de la Recerca de Catalunya
collection Recercat. Dipósit de la Recerca de Catalunya
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869423476620656640
score 15,81155

Similares en LA Referencia